ReviewCureus2017
Cost-Effectiveness of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium Difficile Infection: A Literature Review.
Review in Cureus, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A review on antibiotic and non-antibiotic decolonization strategies of multidrug-resistant bacteria in the gastrointestinal tract.Infection · 2026Review
- [Modulation of the gut microbiome for the eradication of multidrug-resistant pathogens: current approaches and perspectives].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Evaluation of the antibacterial activity of the natural product α-mangostin against Clostridioides difficile.PloS one · 2026Article
- Lurking Danger: Emerging Evidence.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer.International journal of molecular sciences · 2023Review
- Review
- Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.Journal of clinical microbiology · 2022Article
- Gut Microbiome Modulation and Faecal Microbiota Transplantation Following Allogenic Hematopoietic Stem Cell Transplantation.Cancers · 2021Review
- Gut Dysbiosis andFrontiers in microbiology · 2021Review
- Safety of fecal microbiota transplantation forTherapeutic advances in gastroenterology · 2021Review
- Recent advances in the treatment ofFaculty reviews · 2020Review
- The Efficacy of Washed Microbiota Transplantation onGastroenterology research and practice · 2020Article
- Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?Current diabetes reports · 2019Review
- The microbiome, cancer, and cancer therapy.Nature medicine · 2019Review
- Cost savings following faecal microbiota transplantation for recurrentTherapeutic advances in gastroenterology · 2019Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.